share_log

Processa Pharmaceuticals | 8-K: Current report

Processa Pharmaceuticals | 8-K: Current report

Processa Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  07/02 12:58

Moomoo AI 已提取核心訊息

On June 28, 2024, Processa Pharmaceuticals held its 2024 Annual Meeting of Shareholders, with a quorum achieved through the presence of shareholders representing a majority of the voting power. During the meeting, shareholders voted on several key proposals. All six director nominees were elected to serve until the next annual meeting. Additionally, an amendment to increase the number of shares available under the Processa Pharmaceuticals 2019 Omnibus Incentive Plan by 500,000 was approved. BD & Company, Inc. was ratified as the independent registered public accounting firm for the year 2024. Furthermore, the compensation of the company's named executive officers received approval through an advisory vote. The results of these votes were filed with the SEC in a Form 8-K report, signed by James Stanker on July 1, 2024.
On June 28, 2024, Processa Pharmaceuticals held its 2024 Annual Meeting of Shareholders, with a quorum achieved through the presence of shareholders representing a majority of the voting power. During the meeting, shareholders voted on several key proposals. All six director nominees were elected to serve until the next annual meeting. Additionally, an amendment to increase the number of shares available under the Processa Pharmaceuticals 2019 Omnibus Incentive Plan by 500,000 was approved. BD & Company, Inc. was ratified as the independent registered public accounting firm for the year 2024. Furthermore, the compensation of the company's named executive officers received approval through an advisory vote. The results of these votes were filed with the SEC in a Form 8-K report, signed by James Stanker on July 1, 2024.
2024年6月28日，processa pharmaceuticals舉行了2024年股東年度大會，通過股東代表佔表決權的大多數出席，達成法定人數。在會議期間，股東就幾項重要提案進行了投票。所有6名董事提名人都當選，任期到下次年度大會。此外，批准了一項修正案，將Processa Pharmaceuticals 2019年股份激勵計劃下可用股份數量增加了50萬股。BD&Company，Inc.被確認爲獨立的註冊公共會計師事務所，服務於2024年。此外，公司的高管薪酬經過顧問投票獲得批准。這些投票的結果在James Stanker於2024年7月1日簽署的8-K表中提交給了SEC。
2024年6月28日，processa pharmaceuticals舉行了2024年股東年度大會，通過股東代表佔表決權的大多數出席，達成法定人數。在會議期間，股東就幾項重要提案進行了投票。所有6名董事提名人都當選，任期到下次年度大會。此外，批准了一項修正案，將Processa Pharmaceuticals 2019年股份激勵計劃下可用股份數量增加了50萬股。BD&Company，Inc.被確認爲獨立的註冊公共會計師事務所，服務於2024年。此外，公司的高管薪酬經過顧問投票獲得批准。這些投票的結果在James Stanker於2024年7月1日簽署的8-K表中提交給了SEC。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間